The Use of Epicardial Electrogram as a Simple Guide to Select the Optimal Site of Left Ventricular Pacing in Cardiac Resynchronization Therapy

Table 1

Comparison of clinical characteristics in responders and nonresponders.

	Responders 𝑁=47	Nonresponders 𝑁=25	P
Age (years)	70±7	72±8	.36
NIDCM (%)	72	60	.29
SR at implant (%)	89	92	.72
NYHA class	3.3±0.5	3.1±0.7	.37
NYHA class
Class III (%)	69	73	.71
Class IV (%)	31	27
Baseline treatment
Beta-blocker (%)	67	65	.91
ACE inhibitor (%)	73	81	.48
ARA (%)	22	12	.35
Diuretics (%)	98	92	.55
Spironolactone	38	42	.71
Digoxin (%)	27	31	.71
Statin (%)	40	42	.85
Treatment at followup
Beta-blocker (%)	80	65	.17
ACE inhibitor (%)	78	65	.26
ARA (%)	29	23	.59
Diuretics (%)	98	100	1
Spironolactone	27	42	.18
Digoxin (%)	24	42	.12
Statin (%)	49	46	.82
Change of treatment during followup (%)	89	89	1
6-minute walked distance (m)	354±126	348±119	.88
Follow-up duration (months)	32.1±20.9	27.3±19.1	.35
Δ NYHA class	−1.6±0.7	−0.2±0.9	<.001

Abbreviations used: SR: sinus rhythm, NIDCM: nonischemic dilated cardiomyopathy, NYHA class: New York Heart Association functional class, ACE inhibitors: angiotensin converting enzyme inhibitors, ARA: angiotensin receptor antagonist, Δ NYHA: difference of NYHA class between followup and baseline.